<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Gefitinib</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00317</strong>&#160; (APRD00997, DB07998)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00317/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00317/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00317.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00317.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00317.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00317.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00317.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00317">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Iressa</td><td>AstraZeneca</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>184475-35-2</td></tr><tr><th>Weight</th><td>Average: 446.902<br>Monoisotopic: 446.152096566</td></tr><tr><th>Chemical Formula</th><td>C<sub>22</sub>H<sub>24</sub>ClFN<sub>4</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>XGALLCVXEZPNRQ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Naphthyridines</td></tr><tr><th>Subclass</th><td>Quinazolines</td></tr><tr><th>Direct parent</th><td>Quinazolinamines</td></tr><tr><th>Alternative parents</th><td>Anisoles; Aminopyrimidines and Derivatives; Alkyl Aryl Ethers; Chlorobenzenes; Fluorobenzenes; Morpholines; Aryl Chlorides; Aryl Fluorides; Tertiary Amines; Polyamines; Secondary Amines; Organochlorides; Organofluorides</td></tr><tr><th>Substituents</th><td>anisole; phenol ether; fluorobenzene; aminopyrimidine; chlorobenzene; alkyl aryl ether; oxazinane; aryl halide; pyrimidine; benzene; aryl chloride; morpholine; aryl fluoride; tertiary amine; ether; secondary amine; polyamine; organochloride; organohalogen; organofluoride; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.</td></tr><tr><th>Pharmacodynamics</th><td>Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.</td></tr><tr><th>Mechanism of action</th><td>Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the Ras signal transduction cascade is inhibited; and malignant cells are inhibited. Gefitinib is the first selective inhibitor of the EGFR tyrosine kinase which is also referred to as Her1 or ErbB-1. EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. Overexpression leads to inappropriate activation of the apoptotic Ras signal transduction cascade, eventually leading to uncontrolled cell proliferation.</td></tr><tr><th>Absorption</th><td>Absorbed slowly after oral administration with a mean bioavailability of 60%. Peak plasma levels occurs 3-7 hours post-administration. Food does not affect the bioavailability of gefitinib. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1400 L [IV administration]</li>
</ul></td></tr><tr><th>Protein binding</th><td>90% primarily to serum albumin and alpha 1-acid glycoproteins (independent of drug concentrations).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic via CYP3A4. Three sites of biotransformation have been identified: metabolism of the N-propoxymorpholino-group, demethylation of the methoxy-substituent on the quinazoline, and oxidative defluorination of the halogenated phenyl group.</p></td></tr><tr><th>Route of elimination</th><td>Elimination is by metabolism (primarily CYP3A4) and excretion in feces.  Excretion is predominantly via the feces (86%), with renal elimination of drug and metabolites accounting for less than 4% of the administered dose.</td></tr><tr><th>Half life</th><td>48 hours [IV administration] </td></tr><tr><th>Clearance</th><td><ul>
	<li>595 mL/min [IV administration]</li>
</ul></td></tr><tr><th>Toxicity</th><td>The acute toxicity of gefitinib up to 500 mg in clinical studies has been low. In non-clinical studies, a single dose of 12,000 mg/m<sup>2</sup> (about 80 times the recommended clinical dose on a mg/m<sup>2</sup> basis) was lethal to rats. Half this dose caused no mortality in mice. Symptoms of overdose include diarrhea and skin rash.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Gefitinib Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Epidermal growth factor receptor<br>Gene symbol: EGFR<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P00533" target="_blank">P00533 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>G719A/C OR (L858R and L861Q)</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>Associated with enhanced activation of the EGFR tyrosine kinase in patients with non-small cell lung cancer (NSCLC) recieving  tyrosine kinase inhibitor therapy.</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15118073" target="_blank" title='# Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15118073'>15118073 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>ATP-binding cassette sub-family G member 2<br>Gene symbol: ABCG2<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q9UNQ0" target="_blank">Q9UNQ0 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2231142" target="_blank">rs2231142 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A Allele</td><td>Diarrhea</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17148776" target="_blank" title="Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD: Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.">17148776 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>ATP-binding cassette sub-family G member 2<br>Gene symbol: ABCG2<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q9UNQ0" target="_blank">Q9UNQ0 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2231142" target="_blank">rs2231142 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A allele</td><td>In non-small lung cancer patients, those that are heterozygous (ABCG2 421C&gt;A) have a higher risk of diarrhea.</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17148776" target="_blank" title='# Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD: Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17148776'>17148776 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9961</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9759</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5934</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.693</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7361</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.923</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5543</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7853</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6447</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6354</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.7516</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6272</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6536</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.644</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.8206</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.9309</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9218
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5141 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.758
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8019
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Astrazeneca uk ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.gene.com">Genentech Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>250 mg </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Gefitinib may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01351">Amobarbital</a></td><td>The CYP3A4 inducer, amobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Gefitinib may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB01352">Aprobarbital</a></td><td>The CYP3A4 inducer, aprobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00237">Butabarbital</a></td><td>The CYP3A4 inducer, butabarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>The CYP3A4 inducer, butalbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB01353">Butethal</a></td><td>The CYP3A4 inducer, butethal, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>The CYP3A4 inducer, carbamazepine, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of gefitinib</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Gefitinib may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>The CYP3A4 inducer, dihydroquinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of gefitinib</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The CYP3A4 inducer, ethotoin, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Gefitinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase gefitinib dosage, if clinically appropriate, and to monitor for gefitinib therapy for efficacy and toxicity. </td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The CYP3A4 inducer, fosphenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB01354">Heptabarbital</a></td><td>The CYP3A4 inducer, heptabarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB01355">Hexobarbital</a></td><td>The CYP3A4 inducer, hexobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of gefitinib. Monitor for changes in the therapeutic and adverse effects of gefitinib if itraconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of gefitinib</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The CYP3A4 inducer, mephenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00474">Methohexital</a></td><td>The CYP3A4 inducer, methohexital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00849">Methylphenobarbital</a></td><td>The CYP3A4 inducer, methylphenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00312">Pentobarbital</a></td><td>The CYP3A4 inducer, pentobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>The CYP3A4 inducer, phenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The CYP3A4 inducer, phenytoin, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>The CYP3A4 inducer, primidone, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>The CYP3A4 inducer, quinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin reduces levels and efficacy of gefitinib</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of gefitinib</td></tr><tr><td><a href="/drugs/DB00418">Secobarbital</a></td><td>The CYP3A4 inducer, secobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>The CYP3A4 inducer, St. John's Wort, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00306">Talbutal</a></td><td>The CYP3A4 inducer, talbutal, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Gefitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Gefitinib if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The BCRP/ABCG2 inhibitor, Gefitnib, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Gefitinib is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of gefitinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of gefitinib if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Gefitinib may increase the anticoagulant effect of warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid fresh grapefruit and its juice during therapy as grapefruit may increase serum product levels.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>